Modulation of Immunity-related Gene Expression Under the Chinese Herbal Formula SS-1 Treatment for Sjögren's Syndrome
Sponsor: Chang Gung Memorial Hospital
This PHASE2 trial investigates Sjögren's Syndrome and is currently ongoing. Chang Gung Memorial Hospital leads this study, which shows 7 recorded versions since 2014 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Unknown PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE2
Status: Unknown Status → Unknown
-
Jan 2021 — Jul 2024 [monthly]
Unknown Status PHASE2
-
Sep 2018 — Jan 2021 [monthly]
Unknown Status PHASE2
Status: Recruiting → Unknown Status
-
Jun 2018 — Sep 2018 [monthly]
Recruiting PHASE2
▶ Show 2 earlier versions
-
Sep 2017 — Jun 2018 [monthly]
Recruiting PHASE2
-
Jan 2017 — Sep 2017 [monthly]
Recruiting PHASE2
First recorded
Feb 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Chang Gung Memorial Hospital
- China Medical University Hospital
- China Medical University, China
- National Research Program for Biopharmaceuticals, Taiwan
For direct contact, visit the study record on ClinicalTrials.gov .